Valuation: Erasca, Inc.

Market Cap 5.71B 5B 4.6B 4.27B 8.1B 542B 8.23B 55.22B 21.47B 267B 21.44B 20.97B 924B P/E 2026 *
-19.1x
P/E 2027 * -32.5x
Enterprise Value 5.04B 4.41B 4.06B 3.77B 7.15B 478B 7.26B 48.72B 18.95B 236B 18.91B 18.5B 816B EV / Sales 2026 *
-
EV / Sales 2027 * 9,978x
Free-Float
89.34%
Yield 2026 *
-
Yield 2027 * -
1 day-1.09%
1 week+2.57%
Current month+0.33%
1 month+42.81%
3 months+8.50%
6 months+216.35%
Current year+394.09%
1 week 17.24
Extreme 17.24
19.3
1 month 12.26
Extreme 12.26
19.3
Current year 3.36
Extreme 3.36
24.28
1 year 1.33
Extreme 1.3301
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer - 25/05/2022
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap.
06-26Free

Director

29,888 0.0096%
06-26Free

Director

29,888 0.0096%
06-26Free

Director

29,888 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%+2.57%+1,158.90%+549.47% 5.71B
-0.03%+4.87%+2.58%+9.03% 49.74B
-0.62%+1.34%+421.47%+598.36% 40.49B
-1.53%+4.46%+24.23%+57.75% 34.35B
-3.04%-0.54%+22.89%-7.89% 34.75B
+1.31%-0.56%+5.12%+33.90% 26.98B
+1.42%+1.11% - - 16.58B
-4.22%-3.65%+62.40%+116.61% 15.6B
-1.42%+7.39%+105.71%+103.54% 14.27B
-2.93%-2.28%+12.10%+17.49% 13.76B
Average -1.25%+3.81%+201.71%+164.25% 25.22B
Weighted average by Cap. -1.08%+4.49%+119.77%+144.17%

Financials

2026 *2027 *
Net sales - 500K 438K 403K 374K 710K 47.45M 721K 4.84M 1.88M 23.42M 1.88M 1.84M 80.95M
Net income -299M -261M -241M -223M -424M -28.34B -430M -2.89B -1.12B -13.98B -1.12B -1.1B -48.33B -189M -166M -153M -142M -269M -17.97B -273M -1.83B -712M -8.87B -711M -695M -30.66B
Net Debt -672M -588M -542M -502M -953M -63.75B -969M -6.5B -2.53B -31.46B -2.52B -2.47B -109B -721M -631M -581M -539M -1.02B -68.4B -1.04B -6.97B -2.71B -33.75B -2.71B -2.65B -117B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
08/07/26 $18.43 +0.38% 1,760,159
07/07/26 $18.36 -2.60% 5,241,622
06/07/26 $18.85 +2.06% 4,539,684
02/07/26 $18.47 +3.07% 4,096,130
01/07/26 $17.92 -2.18% 3,890,130
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.36USD
Average target price
21.00USD
Spread / Average Target
+14.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock